TL;DR
This study reveals that mandatory fresh tissue biopsies for biomarker testing in clinical trials significantly delay treatment initiation. While these delays didn't impact overall trial duration or progression-free survival in this cohort, they were often not clearly communicated in informed consent forms, potentially impacting patient expectations.
What Problem Does This Paper Address?
The increasing use of targeted therapies and immunotherapies in oncology relies heavily on identifying specific biomarkers within tumor tissue. This has led to a growing requirement for fresh tumor biopsies for biomarker analysis as a prerequisite for enrolling patients in clinical trials. While previous studies hinted at this, the authors aimed to confirm whether these mandatory biopsies indeed lead to delays in starting treatment and to quantify this impact. This is crucial because cancer patients often have limited time and are seeking the most effective treatments promptly. Understanding these delays is vital for optimizing clinical trial design and patient care.
Methods
The researchers conducted a retrospective analysis of 76 patients enrolled in clinical trials at the USC Norris Comprehensive Cancer Center between January 2013 and May 2018. They divided patients into two groups: those who required a fresh research biopsy before treatment (research biopsy group) and those who did not, using archival tissue instead (no biopsy group). They meticulously collected data from electronic medical records, focusing on the time from biopsy consent or initial clinical trial consent to treatment initiation, time on trial until disease progression, and total time on trial. Statistical analysis, including unpaired t-tests, was used to compare outcomes between the two groups.
Datasets
The study utilized retrospective data from the electronic medical records of 76 patients treated at the USC Norris Comprehensive Cancer Center. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- The "Biopsy Bottleneck": The core finding is that the logistical requirements of obtaining and processing fresh tissue for biomarker analysis create a significant bottleneck, delaying the start of potentially life-saving treatments.
- Informed Consent Gap: A concerning observation is that the informed consent documents for trials requiring these biopsies often failed to adequately communicate the potential for treatment delays, leaving patients and clinicians potentially unaware of this consequence.
- No Immediate Survival Impact (in this cohort): While delays were observed, this particular study did not find a statistically significant difference in the time patients spent on trial or the time until disease progression between the biopsy and no-biopsy groups. This suggests that while initiation is delayed, the treatment itself might still be effective for a similar duration once started.
- The Rise of Liquid Biopsies: The authors highlight liquid biopsies (e.g., cfDNA, ctDNA from blood or saliva) as a promising alternative that could potentially circumvent the delays and complications associated with tissue biopsies, allowing for faster enrollment and more frequent monitoring.
Key Results
- Trials requiring a fresh research biopsy had a significantly longer median screening duration: 30 days compared to 14 days for trials that did not require a biopsy (p < 0.0001).
- The research biopsy group experienced a median of 30 days from biopsy consent or initial clinical trial consent to treatment initiation, while the no-biopsy group had a median of 14 days.
- While 9.1% of patients in the research biopsy group experienced biopsy complications, no patients dropped out of the study due to these complications.
- No statistically significant differences were found in the median time on trial before disease progression (112 vs. 119 days) or the total time on clinical trial (112 vs. 105 days) between the groups.
Limitations and Future Work
The authors acknowledge several limitations:
- Single Institution Study: The findings are based on data from one cancer center, which may limit generalizability.
- Heterogeneity: The study included a mix of malignancies and clinical trial treatments, which could introduce variability.
- Retrospective and Non-Randomized: The retrospective nature means causality cannot be definitively proven, and the lack of randomization might introduce biases.
Future work should focus on:
- Prospective Studies: Designing prospective studies to better understand the impact of these delays on patient outcomes and survival.
- Informed Consent Improvement: Revising informed consent forms to clearly articulate the potential for treatment delays associated with mandatory research biopsies.
- Liquid Biopsy Research: Further investigation into the accuracy and utility of liquid biopsies for biomarker testing in clinical trials to streamline the process.
- Biomarker Dynamic Assessment: Developing better methods to assess whether fresh biopsies are truly necessary by comparing them with archival tissue and understanding biomarker dynamics.
Summary updated